## PART B : Investigation and Management


- Have the ACDP Guidelines caused you any problems in laboratory investigation of haemophiliacs :
- 2, Have the Guidelines caused you any problems in the haematological investigation of other patients :
- 3. Do your laboratories meet the requirements :
- Have you had any financial difficulties in meeting the Guidelines :
- Have any patients suffered because of the Guidelines :
- 6. Have there been any problems on the wards etc because of AIDS :

If so :

Have these problems been aggravated by the ACDP Guidelines :

Have these problems been ameliorated by the Guidelines :

Please Answer Yes or No



Ast.

No

No

If you have any more detailed observations on the ACDP Guidelines and their implementation, I would be grateful if you could detail these in a separate letter.

N. TRELAND. DIRECTOR'S NAME CENTRE.

## PART A : Haemophilia Therapy

Are you still using unheated commercial factor VIII :

If "yes" - do you use it for children :

2. Are you still using unheated BPL factor VIII :

lf "yes" - do you use it for children :

- 3. Are you using cryoprecipitate :
- Are you using heat-treated commercial factor VIII :
- 5. Are you using heat-treated BPL factor VIII :
- 6. Are you still using unheated BPL factor IX :
- 7. Are you using heat-treated commercial factor IX :
- Have you had any significant financial restrictions on purchase of concentrates :

Please Answer

Yes or No

NO

occasionily for children

accasionally No No No.

No.

The N. Juland sentre is here the formed with boat the led WII preterie from sectleard, and pahated IX malenail from the Jerme Acrice GRO-C

Coleg Meddygaeth Prifysgol Cymru

University of Wales College of Medicine

Department of Haematology, Heath Park, Cardiff CF4 4XN Tel. 0222-755944

9th April, 1985.

Dear Director,

## Re: Haemophilia Investigation And Treatment.

I am sorry to inflict yet another questionnaire upon you but I would be grateful if you could complete the brief one enclosed and return it to me in the addressed envelope, before the end of April.

The information is needed because I have been asked to participate in the assessment and revision of the ACDP Guidelines and it would also help me to assess the demand for heat-treated factor VIII and IX concentrates. If you have any more detailed observations, I would be grateful if you could set these out in a separate letter.

Thank you for your help.

Yours sincerely,

GRO-C A.L. Bloom.



Professor A. L. Bloom